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Bone turnoverWnt activation by inhibiting glycogen synthase kinase 3 (GSK-3) causes bone anabolism in rodents making GSK-
3 a potential therapeutic target for osteoporotic and osteolytic metastatic bone disease. To understand the wnt
pathway related to human disease translation, the ability of 3 potent inhibitors of GSK-3 (AZD2858, AR79,
AZ13282107) to 1) drive osteoblast differentiation and mineralisation using human adipose-derived stem cells
(hADSC) in vitro; and 2) stimulate rat bone formation in vivowas investigated. Bone anabolism/resorption was
determined using clinically relevant serum biomarkers as indicators of bone turnover and bone formation
assessed in femurs by histopathology and pQCT/μCT imaging.
GSK-3 inhibitors caused β-catenin stabilisation in human and rat mesenchymal stem cells, stimulated hADSC
commitment towards osteoblasts and osteogenic mineralisation in vitro. AZD2858 produced time-dependent
changes in serum bone turnover biomarkers and increased bone mass over 28 days exposure in rats. After
7 days, AZD2858, AR79 or AZ13282107 exposure increased the bone formation biomarker P1NP, and reduced
the resorption biomarker TRAcP-5b, indicating increased bone anabolism and reduced resorption in rats. This
biomarker proﬁle was differentiated from anabolic agent PTH1–34 or the anti-resorptive Alendronate-induced
changes. Increased bone formation in cortical and cancellous bone as assessed by femur histopathology sup-
ported biomarker changes. 14 day AR79 treatment increased bone mineral density and trabecular thickness,
and decreased trabecular number and connectivity assessed by pQCT/μCT.
GSK-3 inhibition caused hADSC osteoblastogenesis and mineralisation in vitro. Increased femur bone mass asso-
ciated with changes in bone turnover biomarkers conﬁrmed in vivo bone formation and indicated uncoupling of
bone formation and resorption.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.Introduction
The process of bone remodelling involves tightly coupled bone re-
sorption and formation activities and dysregulation of bone turnover
can lead to a number of bone disorders such as osteopetrosis and osteo-
porosis. Inmalignant diseases, bone destruction through increased boneca at the time of submission of
AstraZeneca R&D, Alderley Park
. Gilmour).
c. Open access under CC BY-NC-SA liceresorption produces osteolytic lesions and is a characteristic feature
of multiple myeloma and breast cancer metastatic disease (Theriault,
2012). Current therapies aimed for osteoporotic and osteolytic bone
diseases are primarily aimed at reducing bone resorption. However,
stimulating anabolic activity is an alternative and complementary
therapeutic strategy. Therefore, understanding of the biochemical path-
ways governing osteoblast differentiation and function has aided
the search for anabolic therapies and recent research has highlighted
the importance ofWnt signalling in bone formation. CanonicalWnt sig-
nalling is critical for osteoblast maturation and function and activation
of Wnt signalling through inhibition of constitutively active GSK-3
results in induction of β-catenin and Runx2 transcriptional activities
(Hartmann, 2006; Kugimiya et al., 2007; Monroe et al., 2012;
Reinhold and Naski, 2007). In vitro, GSK-3 inhibition leads to osteoblast
differentiation in a C3H10T1/2 murine mesenchymal stem cell (MSC)nse.
400 P.S. Gilmour et al. / Toxicology and Applied Pharmacology 272 (2013) 399–407population (Kulkarni et al., 2006). Accordingly in vivo, haploinsufﬁcient
GSK-3βmice display increased bone density in comparison to wildtype
mice (Kugimiya et al., 2007) and small molecule inhibitors of GSK-3α/
β have demonstrated increased bone mass in normal and ovariecto-
mized rodent models (Clement-Lacroix et al., 2005; Gambardella
et al., 2011; Kulkarni et al., 2006; Marsell et al., 2012).
In order to determine the role of GSK-3 in humanosteoblastogenesis,
three structurally diverse, potent GSK-3 inhibitorswere tested in hADSC
assays in vitro. We have assessed the ability of these GSK-3 inhibitors
to stimulate canonical Wnt/β-catenin signalling through β-catenin
stabilisation and osteogenicmineralisation. In addition,we have studied
the commitment of hADSC towards osteoblastogenesis through the
assessment of protein transcriptional co-activator with PDZ-binding
motif (TAZ), and the osteoblast-speciﬁc marker Osterix. TAZ modulates
the activity of the critical osteoblast transcription factor runt-related
transcription factor 2 (RUNX2) and PPARγ duringMSC lineage commit-
ment (Hong et al., 2005) and has recently been reported as a down-
stream component of the Wnt/β-catenin signalling cascade (Azzolin
et al., 2012). Osterix has been reported to be essential for osteoblast
differentiation and bone formation as exempliﬁed by the complete
lack of osteoblast differentiation and maturation in osterix-null mice
(Nakashima et al., 2002). In order to demonstate translation of these
in vitro ﬁndings to bone anabolism in an intact system, each GSK-3 in-
hibitor was dosed daily to rats, and bone formation in vivowas investi-
gated by quantifying changes in serum biomarkers of bone turnover
and femur bone changes. One challenge for pre-clinical assessment of
potential bone anabolic agents is the ability to measure changes over a
short period of time in in vivo models as many agents that modulate
bone turnover have been tested in lengthy disease models such as the
ovariectomized rat model. Therefore, serum bone turnover markers,
which are used in the clinical setting, were used in these studies to eval-
uate treatment effectiveness beforemature bone formation could be ob-
served in healthy rats. Initially, a time course of changes in serum bone
turnover biomarkerswas established following daily dosing of AZD2858
which has known anabolic activity in rats (Marsell et al., 2012). Then,
the effect of three different GSK-3 inhibitors (AZD2858, AR79 and
AZ13282107), PTH1–34 and Alendronate on serum biomarkers in short
term rat studies (7 days) were assessed by quantifying N-terminal
propeptide of type I procollagen (P1NP), a marker of bone anabolism
(Hale et al., 2007) and osteoblast activity and Tartrate-resistant acid
phosphatase (TRAcP-5b) a marker of bone metabolism (Halleen et al.,
2006). In addition, conﬁrmation of bone formation was assessed using
histology and imaging (pQCT, μCT) of femurs.
Materials and methods
Small molecule compounds AR79, AZD2858 and AZ13282107
were synthesised at AstraZeneca R&D, Loughborough UK (structures
in Fig. 1).
GSK-3 and kinase selectivity assays. The potency of compounds at
GSK-3β and cyclin-dependent protein kinase 2 (CDK2, kinase with
closest homology to GSK-3β) was assessed using Z-LYTE™ Kinase assay
kit (Invitrogen, UK) in the presence of 7 and 80 μM ATP respectively.Fig. 1. Small molecule GSK-3 inhibA ratiometric method was used to calculate the ratio of donor emission
(445 nm) to acceptor emission (520 nm) after excitation of the donor
ﬂuorophore at 400 nm to quantitate the reaction progress. Kinase selec-
tivity with AR79, AZD2858 and AZ13282107 were determined using the
KinaseProﬁler Service (Millipore, Watford, UK) or University of Dundee
Kinase (MRCProtein PhosphorylationUnit, UK). Over 80different kinases
were assessed at a single concentration of 1 or 10 μM of AR79, AZD2858
and AZ13282107. Concentration-inhibition 10-point curves to com-
pounds that showed activity were constructed to determine pIC50 esti-
mations. Also, in some kinase assays these pIC50 estimations were
converted to binding afﬁnity values (pKi) using the Cheng–Prussoff equa-
tion to correct for the concentration of ATP used.
β-catenin stabilisation in mesenchymal stem cells. Human adipose-
derived stem cells (hADSC; Invitrogen, UK) and rat MSCs (isolated
from bonemarrow of Sprague Dawley rats at≤8 weeks after gestation;
Invitrogen, UK) were cultured in a basal media of Dulbecco's Modiﬁed
Eagle's Medium (DMEM; Sigma-Aldrich, UK) containing 5% (v/v) foetal
bovine serum (FBS, Gibco, UK) and 2 mM GlutaMax (Invitrogen, UK).
Cells were seeded in basal media into 96-well plates (3–5000 cells/well)
for 18 h before treatment with AZD2858, AR79 or AZ13282107 (0.3 nM
to 20 mM). After 24 h, β-catenin stabilisation was measured as previ-
ously described (Gambardella et al., 2011).
Osteoblast-speciﬁc marker expression. hADSC were seeded at a densi-
ty of 5000 cells/well into black 96-well Viewplates (Perkin-Elmer Inc.,
UK) in basal media (as detailed above). All cells were incubated at
37 °C in 5% CO2/95% air humidiﬁed atmosphere. After overnight incuba-
tion, basal media was replaced and compounds, at concentrations
of 6 nM to 20 μM, or 0.2% DMSO vehicle were added. After 18 h,
cells were ﬁxed in 4% paraformaldehyde (PFA) for 20 min followed by
washing in PBS. The cells were blocked in PBS supplemented with
1.1% BSA (Sigma-Aldrich) and 0.2% Triton X-100 for 30 min at room
temperature. Anti-osterix (1:50 dilution, ab22552, Abcam, UK) and
TAZ antibody (1:500 dilution, #2149, Cell Signalling Technology) were
added overnight at 4 °C in blocking buffer, followed by addition of
Alexa Fluor AF647 donkey anti-rabbit IgG (Invitrogen, UK) and 1 μM
Hoechst 33342 in blocking buffer for 1 h at room temperature. Cells
were washed and stored in PBS at 4 °C prior to image acquisition and
analysis, using an in-built object intensity algorithm, on an IN Cell
Analyzer 3000 platform (Amersham Biosciences, UK).
Osteogenic differentiation studies — Alizarin Red staining and automated
image analysis. hADSC were seeded at a density of 5000 cells/cm2
and were cultured in basal media (as above). After overnight incuba-
tion, basal media was replaced and compounds were added. In oste-
ogenic positive control wells, basal media was replaced with an
osteogenic differentiationmedia: phenol red-free DMEMsupplemented
with 5% FBS, 2 mMGlutaMax, 50 μg/ml L-ascorbic acid (Sigma-Aldrich,
UK), 5 mM β-glycerophosphate (Calbiochem, UK), and 10 nM dexa-
methasone (Sigma-Aldrich, UK). Cells were incubated at 37 °C in 5%
CO2 with media and compounds being replaced every 3–4 days over
a 25–28 day time-course. Osteogenic mineralisation was visualised
using Alizarin Red staining. Cells were washed with PBS followed byitors from 3 chemical series.
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The cells were washed three times with PBS before staining with
40 mM Alizarin Red S solution (pH 4.2) for 20 min at room tempera-
ture. After staining, cells were washed three times with PBS, followed
by washes with water to remove non-speciﬁc staining. Plates were
allowed to dry and mineralisation was imaged, at 7.3× magniﬁcation,
using a LeicaM165 FC stereomicroscope. Image analysis was performed
using custom-designed analysis algorithms created using Deﬁniens
Developer XD analysis software (Deﬁniens AG, Germany). Brieﬂy,
mineralisation was quantiﬁed using a combination of pixel contrast, in-
tensity values, and segmentation in the red channel allowing individual
pixels to be classiﬁed as either background (white pseudocolour),
unstained osteoblast (light blue pseudocolour), or mineralized matrix
(medium/dark blue pseudocolour).
Animals and in vivo study protocols. Female Han Wistar (HW) and
Sprague–Dawley (SD) rats (240 to 330 g initial weight) were supplied
by Harlan, UK and Charles River, UK, group housed and acclimatised
for at least 7 days with access to food and water ad libitum. Mature
animals (N11 weeks)were used in these studies to provide a consistent
level of background bone turnover in the absence of rapid adolescent
growth and animals in each experiment were matched for size and
age. All experimental procedures were performed in accordance with
UK Home Ofﬁce regulations under the Animals (Scientiﬁc Procedures)
Act 1986. GSK-3 inhibitors were administered by oral gavage, once-a-
day (UID) following formulation in either water adjusted to pH 3.5
for AZD2858, or water containing 0.5% HPMC (hydroxypropyl)methyl
cellulose, Sigma, Poole, UK) and 0.1% Tween 80 (v/v) (Sigma, Poole,
UK) for AR79 andAZ13282107. PTH1–34 and alendronatewere dissolved
in saline and dosed sub-cutaneously (sc). To establish suitable doses,
plasma levels of AZD2858, AR79 and AZ13282107 were quantiﬁed fol-
lowing a single, oral dose in rats (data not shown). Doses of AR79 and
AZ13282107 were calculated based on achieving a similar plasma AUC
over 24 h to AZD2858 (30 μmol/kg/day, dose shown to stimulate bone
formation in rats Fig. 4). Differences in potency and plasma protein
binding between compoundswere taken into accountwhen calculating
doses. PTH1–34 was administered at 30 μg/kg (sc) every second day
based on bone anabolism reported previously with intermittent dosing
of PTH in this dose range (Fukata et al., 2004). A daily 30 μg/kg (sc)
dose of alendronate was used which has been shown to increase bone
mineral density in a rat arthritis model (Harada et al., 2004). In vivo
studies were designed with time-matched, vehicle treated control
groups and 8–10 animals per group, randomised by weight. Group
sizes were used to give a minimum 80% power to detect 30% change
in the biomarker endpoint. Study 1: 28 day time course with
AZD2858. Naïve HW rats were dosed by orally, UID for 3, 7, 14, 21 or
28 days with AZD2858 (30 μmol/kg/day) or vehicle (pH3.5 adjusted
H2O). Endpoints were determined 24 h following the ﬁnal dose. Study
2: 7 day biomarker study with GSK-3 inhibitors AR79, AZ13282107,
PTH1–34 and Alendronate. Naïve SD rats were dosed with AR79 (11,
32 and 106 μmol/kg/day) or AZ13282107 (7, 23 and 69 μmol/kg/day)
orally, UID for 7 days. PTH1–34 (once every two days) and alendronate
(UID) were dosed (sc) at 30 μg/kg. Study 3: 14 day biomarker and
imaging studies with AR79 (32 μmol/kg/day).
Tissue and blood sampling, analysis of compound levels and serum bone
biomarkers. All animals were fasted for 16 h prior to termination.
Rats were euthanized by intra-peritoneal injection of pentobarbitone
sodium (Euthatal). Blood was collected 24 h after ﬁnal compound
dose and serum was prepared for quantiﬁcation of P1NP and TRAcP-
5b by ELISA (IDS Ltd, UK). Terminal pharmacokinetic (PK) blood sam-
ples in EDTA were taken from the abdominal vena cava of animals and
centrifugation at 12,000 rpm for separation of plasma. Compound levels
were determined by preparing ten standard and three quality control
(QC) samples covering a range of compound concentrations between
1 and 1000 ng/ml in blank SD rat plasma sample. These plasma samplesalong with those from dosed animals were prepared by methanolic
precipitation of proteins. Following centrifugation, supernatants were
analysed by UPLC–MSMS mass spectrometry. Standards and QC's were
within ± 20% of nominal concentration, and linear least-squares re-
gressionwith a 1/×weighting of the peak area ratios (analyte/IS) versus
the nominal concentration of the calibration standards was used to
construct calibration curves. Concentrations of compound in plasma
samples taken from dosed rats were calculated using the calibration
curves. Left femurs were harvested and ﬁxed in 10% neutral buffered
formalin (NBF) prior to histology slide preparation. In some studies,
right femurs were harvested, stored in 10% NBF and retained for pQCT
(peripheral quantitative computed tomography) and μCT (micro-
computed tomography) evaluation.
Slide preparation for histopathology. The left femurs underwent a
rapid decalciﬁcation process for preparation of haematoxylin and
eosin stained sections. The left femurs were ﬁxed in 10% NBF (Pioneer
Chemicals, UK) for 10 days followed by a 5 day decalciﬁcation in 10%
formic acid in water (Fisher Scientiﬁc, UK), changing the decalcifying so-
lutiondaily. Sections 4 μmthick,were cut and stainedwithhaematoxylin
and eosin (H&E). An in-house image analysis programme, developed and
validated using the Zeiss KS400 system (Carl Zeiss Ltd), was used for
the analysis of bone mass within metaphysis regions of haematoxylin
and eosin stained sections of rat femur (see Supplementary Fig. S2).
pQCT/μCT femur analysis. Mineral density and cross-sectional dimen-
sions of bone were measured using pQCT (Tuukkanen et al., 2000),
namely using Norland Stratec XCT Research SA+ equipment with a
Stratec software version 6.0 (Norland StratecMedizintechnik, Birkenfeld,
Germany). The pQCT measurements were performed ex vivo from
metaphysis (especially trabecular bone) and diaphysis (cortical bone)
of each right femurwith a voxel size of 0.07 × 0.07 × 0.5 mm3. See Sup-
plementary Fig. S3 for μCT analysis.
Statistical analysis. For in vitro osteogenicmineralisation studies, data
were expressed as mean ± SEM. The differences between groups were
examined for statistical signiﬁcance using one-way analysis of variance
followed by Tukey's multiple comparison post hoc test, p values b0.05
were considered signiﬁcant. For in vivo studies, each endpointmeasured
per animal was averaged across each treatment group and the results
expressed as mean ± SEM. Results between treatment groups were
compared using non-parametric two-tailedMann–Whitney orWilcoxon
statistical tests as appropriate with a 5% signiﬁcance level. For histo-
pathology assessment, the pathologist was blinded to the treatment
groups.
Results
GSK-3 potency, β-catenin stabilisation and selectivity
AZD2858, AR79 and AZ13282107 are potent GSK-3 inhibitors de-
rived from3 chemical series (Fig. 1, Table 1). All 3 compounds have sim-
ilar potency at bothGSK-3β andGSK-3α enzymes and cause an increase
in β-catenin stabilisation in human and rat MSCs (Table 1, Supplemen-
tary Fig. S1). These effects on β-catenin stabilisation are consistent with
activation of the canonical wnt signalling pathway since the inhibition
of constitutively active GSK-3β prevents β-catenin phosphorylation,
ubiquitination and subsequent proteosomal degradation. Each com-
poundwas tested for selectivity against N80 different kinases at a single
concentration of 1 or 10 μM and off-target hits are summarised in
Table 1. AZD2858 is N70 fold selective for other kinases, receptors and
enzymes. Less than 100 fold selectivity was observed for AR79 at the
following kinases: HIPK2 (no selectivity), PKD1 (8 fold), PIM3 (12 fold)
and DYRK1A (24 fold) compared to GSK-3β potency. AZ13282107 was
200 fold selective to CDK2 and did not show activity against other tar-
gets tested.
Table 1
Potency and selectivity of AR79, AZD2858 and AZ13282107 (AZ107). Results expressed as mean ± SEM, nM, n = 2–5.
Assay Parameter AR79 AZD2858 AZ107
Afﬁnity for target
Human GSK-3β enzyme Ki (measured) 3.2 ± 0.8 5a 3.2 ± 0.5
Human GSK-3α enzyme IC50 5.5 0.9a 3.5 ± 0.3
Kinase selectivity
CDK2 Ki 1000 ± 0.97 N800 nM 631 ± 0.93
HIPK2 IC50 11 717a IA @ 1 μM
PKD1 (PKCmu) IC50 62 85% @ 1 μM IA @ 1 μM
PIM3 IC50 40 1269a IA @ 1 μM
DYRK1A IC50 79 64% @ 1 μM IA @ 1 μM
PRK2 IC50 631 N30000a IA @ 1 μM
FLT1 IC50 3981 94% @ 10 μM IA @1 μM
Fold selectivity to other kinases vs GSK-3β 1× HIPK2
282× CDK2
143× HIPK2
329× CDK2
–
200× CDK2
β-catenin stabilisation:
Human adipose stem cell EC50
416 ± 97 390 ± 45 482 ± 41
Rat mesenchymal stem cells EC50 611 ± 81 234 ± 69 265 ± 20
Bone mineralisation:
Human adipose stem cell
% increase 417.5 ± 15.3 @ 300 nM 230.9 ± 6.8 @ 200 nM 395.5 ± 30.0 @ 300 nM
a (Gambardella et al., 2011), inactive (IA) deﬁned as b40% inhibition.
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To investigate whether GSK-3 inhibition inﬂuenced osteogenic dif-
ferentiation in hADSC, we used immunoﬂuorescence and automated
image analysis to determine the relative protein expression of theFig. 2.Expression of TAZ andOsterix,markers of commitment to osteoblastogenesis in humanA
or 0.2% DMSO vehicle. Results expressed as mean ± SEM, n = 3.osteogenic markers TAZ and osterix following treatment with AZD2858,
AR79, and AZ13282107 (Fig. 2). After 18 h treatment, TAZ expression
was increased 1.3-, 1.4-, and 1.5-fold by AZD2858 (EC50 = 440 nM),
AR79 (EC50 = 5 nM), and AZ13282107 (EC50 = 809 nM), respectively,
relative to DMSO vehicle controls. In addition, osterix expression wasDSC. Treatment (18 h)with 6 nMto 20 μMof (A) AZD2858, (B)AR79 and (C)AZ13282107,
403P.S. Gilmour et al. / Toxicology and Applied Pharmacology 272 (2013) 399–407increased 1.4-, 1.2-, and 1.5-fold in response to treatment with AZD2858
(EC50 = 1.2 μM), AR79, and AZ13282107 (EC50 = 501 nM), respec-
tively, relative to DMSO vehicle controls. Taken together, these data
demonstrate that inhibition of GSK-3 stimulates osteoblastogenesis
in hADSC.Effect of GSK-3 inhibitors on osteogenic differentiation in hADSC
To investigate the role of Wnt/β-catenin activation in the differen-
tiation of hADSC towards osteoblasts, we investigated the effects of
pharmacologic inhibition of GSK-3 on the osteogenic mineralisation
capacity of hADSC (Fig. 3). Mineralisation was assessed using Alizarin
Red staining and, to allow for accurate inter-assay comparison, an auto-
mated image analysis protocol was developed to quantify compound-
induced mineralisation relative to DMSO vehicle control (Fig. 3A).
While the image analysis protocol was developed through the culture
of hADSC in an osteogenic differentiation media; it is important to
note that cells exposed to the GSK-3 inhibitors in this study were
maintained in a basal media without the addition of osteogenic supple-
ments. Incubation of hADSC with AZD2858, AR79, and AZ13282107 led
to a marked increase in osteogenic mineralisation relative to DMSOFig. 3.Osteogenic mineralisation in human ADSC assessed through Alizarin Red staining and qu
of osteogenic mineralisation following 26-days in basal (Reg.) or osteogenic (Diff.) media; or 0
mineralisation following 10 and 25 days in basal media and 0.2% DMSO vehicle and (B) 300 n
by (B) AR79, or (C) AZ13282107, at day 25 (right). Results expressed as mean ± SEM and
*p b 0.05; **p b 0.01; ***p b 0.001 versus vehicle control.vehicle control (Figs. 3B and C, Table 1). These data indicate that inhibi-
tion of GSK-3 enhances osteogenic differentiation of hADSC.
Bone biomarker changes and bone formation in vivo
Time course study with AZD2858
Biomarkers of bone turnoverwere altered over 28 days of daily dos-
ing with AZD2858 (30 μmol/kg/day) in rats with statistically signiﬁcant
increases in P1NP and decreases in TRAcP-5b seen from 3 days of treat-
ment and onwards (Fig. 4). P1NPwas also elevated at 7 and 28 days but
reverted to baseline at 14 and 21 days with AZD2858 (Fig. 4A). Serum
TRAcP-5bwas signiﬁcantly decreased in AZD2858 vs vehicle treated an-
imals at all exposure times up to 28 days (Fig. 4B). Additional biomarker
measurements showed increases in osteocalcin and Rat Laps (rat equiv-
alent of human CTX) after 14 day treatment with AZD2858 (Supple-
mentary Table 1). Histopathology assessment of H&E stained femur
sections observed increases in bone mass (hyperostosis) for all
AZD2858 treated groups beyond day 3 with moderate to severe in-
creases in bone mass in animals treated for 14 days or longer. These
changes were conﬁrmed by image analysis of H&E stained sections
which demonstrated statistically signiﬁcant increases in bone mass in
the epiphysis and metaphysis regions in animals treated for 14 daysantiﬁed using Deﬁniens Developer XD image analysis software. (A) Representative images
.2% DMSO vehicle or 200 nM AZD2858. (B) and (C) Representative images of osteogenic
M AR79, or (C) 300 nM AZ13282107 (left); and quantiﬁcation of mineralisation induced
analysed by ANOVA followed by Tukey's multiple comparison post-hoc test (n = 3).
Fig. 4. Time course of serum bone turnover biomarkers and femur histopathology changes with AZD2858 dosed orally for 3, 7, 14, 21 or 28 days. (A) Serum P1NP and (B) TRAcP-5b levels.
Results expressed as mean ± SEM, *p b 0.05; *p b 0.01; ***p b 0.001 versus relevant vehicle, time match control using Wilcoxon's 2 sided test, n = 6–8 per group. (C) Representative
images of femurs illustrating progression of hyperostosis during the 28 day treatment period. No effects observed following 3 days treatment with AZD2858, mild hyperostosis following
7 days treatment, moderate effects following 14 day treatment and severe hyperostosis observed following 21 or 28 days treatment. All images are presented as H + E ×1 Aperio Sub-
gross Image.
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the epiphysis and metaphysis and was characterised by an increase in
the amount of trabecular bone with a reciprocal decrease in the area
of marrow space (Fig. 4C). In some animals, trabeculae extended into
the marrow cavity of the diaphysis. These changes were accompanied
by a diffuse osteoblast hyperplasia that was characterised by the pres-
ence of large activated cells adhering to the endosteal surfaces of
bone. Changes in cortical bone were less pronounced with generally
only minimal or mild thickening. Therefore, the potential bone anabolic
effect of AZD2858, as indicated by the timedependent changes in serum
biomarkers, was conﬁrmed by increased bone mass in rat femurs over
the 4 week dosing period.
The time course study with AZD2858 demonstrated signiﬁcant
changes in serum bone turnover markers (P1NP and TRAcP-5b) and
femur bone formation after only 7 days of daily dosing. Therefore,
in subsequent in vivo studies, 7 days of dosing with the GSK-3 inhibi-
tors was chosen to assess the activity of AR79 and AZ13282107 on
bone turnover and compared with effects of PTH1–34 or alendronate.
Biomarker changes after 7 days of AR79, AZ13282107, PTH1–34 or
alendronate are illustrated in Fig. 5. Increases in P1NP and inhibition
of TRAcP-5b were seen with AR79 and AZ13282107 compared to vehi-
cle. These biomarker changes were dose related which is consistent
with the dose dependent increase in systemic exposure for each com-
pound (Fig. 6). Intermittent dosing with PTH1–34 produced an increase
in P1NP but did not affect TRAcP-5b (Figs. 5E and F). Conversely,
alendronate inhibited TRAcP-5b but did not affect P1NP. In contrast
to the effects of PTH1–34 and alendronate on bone turnover biomarkers,
inhibitors of GSK-3 altered both P1NP and TRAcP-5b serum levels after
7 days.
Femur histopathology assessment after 7 days of GSK-3 inhibitor
treatment resulted in a dose-related minimal to moderate increase inbone formation (hyperostosis) with both AR79 or AZ13282107. These
changes appeared almost identical to those induced by AZD2858, with
the additional ﬁnding that in a proportion of animals mild focal in-
creases in the thickness of cortical bone were noted together with syno-
vial membrane hyperplasia and ﬁbroplasia.
14 day biomarker, bone mass & 3D-architecture by μCT
A dose related increase in serum P1NP and inhibition of TRAcP-5b
was measured following 14 day treatment with AR79 compared to the
vehicle control (Supplementary Figs. S3A and B). Bone formation in-
duced by AR79 following 14 days exposure was determined by femur
μCT and pQCT analysis of bone. By pQCT, AR79-mediated bone forma-
tion was illustrated by a statistically signiﬁcant increase in total bone
mineral density of 6.6% compared with control animals (Vehicle
764 ± 16: AR79 814 ± 15 mg/cm3, Supplementary Table 2, Figs. S3C
and D). The μCT analysis and quantiﬁcation of bone mass and structure
indicated that AR79 increased trabecular thickness and decreased 3-D
connectivity which is consistent with increased bone formation (Sup-
plementary Table 2). Similar studies in mice, demonstrated an increase
in femur bone mineral density and bone mineral content as determined
by pQCT following 28 day treatment with AR79. Thus, indicating a bone
anabolic effect of AR79 in a second rodent species (data not shown).
Discussion
Through in vitro and in vivo studies using three novel inhibitors of
GSK-3, we have demonstrated that GSK-3 inhibition results in commit-
ment of human MSCs towards osteoblasts and mineralisation, a pro-
bone formation phenotype that translates in vivo to serum bone turn-
over biomarker changes consistent with increased bone formation and
reduced resorption in rats.
Fig. 5.Differential effects of GSK3 inhibitors, PTH1–34 and Alendronate on serumbone turnover biomarkers (P1NP, TRAcP-5b) following 7 days of dosingwith AR79, AZ13282107 (AZ107),
PTH1–34 or Alendronate. (A, B) Rats were dosed with AR79 oral UID, (C,D) AZ107 oral UID or (E, F) AR79 (oral UID), PTH1–34 or Alendronate (sc) Results expressed as mean ± SEM,
*p b 0.05; *p b 0.01; ***p b 0.001 versus relevant vehicle control using Mann–Whitney, n = 10 per group.
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quences on osteoblastogenesis remain controversial and, while a sig-
niﬁcant body of literature describe that Wnt/β-catenin activationFig. 6. Relationship between systemic plasma exposure of AZD2858, AR79 and AZ13282107 and
after 7th oral dose and plasma exposures normalised for differences in potency at GSK-3 and ppromotes osteogenic differentiation (Bain et al., 2003; Eijken et al.,
2008; Gambardella et al., 2011; Krause et al., 2010; Marsell et al.,
2012), it is important to note that there are also reports suggestingserum biomarker changes (A) Serum P1NP and (B) TRAcP-5b levels (samples taken 24 h
lasma protein binding). Results expressed as mean data for each treatment group.
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RNA (siRNA)-mediated GSK-3 silencing and pharmacologic agents in-
hibits the osteogenic differentiation of mesenchymal stem cells (Huh
et al., 2013; Zaragosi et al., 2008). Nevertheless, our studies demon-
strate that activation of the Wnt/β-catenin signalling cascade stimu-
lates osteogenesis. Increased TAZ expression is consistent with the
commitment of MSCs towards osteoblasts. TAZ has been reported to
enhance osteoblastogenesis and suppress the differentiation of MSCs
towards adipocytes. In addition, TAZ-deﬁcient MSCs have been shown
to be predisposed to adipocyte, rather than osteoblast, differentiation
(Hong and Yaffe, 2006; Hong et al., 2005). Where TAZ expression is
suppressed, as with elevated tumour necrosis factor-α, the osteogenic
potential of MSCs is impaired (Li et al., 2007). Furthermore, recent
studies in Wnt-3A-treated murine ST-2 bone marrow stromal cells
and primary MSCs exposed to recombinant Dkk-1, an extracellular
Wnt antagonist, indicate stimulation of Wnt/β-catenin signalling pro-
motes MSC differentiation towards osteoblasts through stabilisation
of TAZ (Azzolin et al., 2012). The canonical Wnt/β-catenin pathway is
complex however with its activity regulated by multiple Wnt ligands,
Wnt receptors, and numerous soluble inhibitors acting at different
points in the signalling cascade to regulate its activity (Clevers and
Nusse, 2012). This complexity, combined with the differences in MSC
source, species investigated, study protocols, and treatment duration
may contribute to the conﬂicting published data. In our own studies,
the increase in osterix expression in hADSC following exposure to
GSK-3 inhibitors indicates an increased commitment of cells towards
an osteoblast phenotype. However, since recent reports have shown
that osterix can itself inhibit the Wnt/β-catenin pathway, possibly
through a synergistic interaction with hypoxia-inducible factor-1α
(HIF-1α) (Chen et al., 2012; Zhang et al., 2008), further studies are re-
quired to understand the temporal effects of GSK-3 inhibition on osteo-
genesis. Nevertheless, the increased expression of TAZ and osterix and
mineralisation in hADSC following treatment with AZD2858, AR79,
and AZ13282107 observed in our studies are consistent with the hy-
pothesis that inhibition of GSK-3 promotes osteoblastogenesis.
In healthy rats, repeat dosing with these three novel GSK-3 inhibi-
tors led to changes in two biomarkers of bone metabolism, suggesting
an uncoupling of the normal balance between bone resorption and
formation, which resulted in a net increase in bone formation. Time de-
pendent changes in several bone biomarkers were observed from day 3
onwards with AZD2858. All three GSK-3 inhibitors produced an in-
crease in P1NP and a reduction in TRAcP-5b after 7 days of dosing in
rats which was associated with an increase in bone mass in femurs.
The increase in bone mass (imaging/histology) seen with AZD2858 is
consistent with previous publications where daily dosing for 2 weeks
in normal rats produced an increase in both trabecular and cortical
bone mass (Marsell et al., 2012). In mice, AZD2858 has been shown to
cause expansion of the mesenchymal progenitor cell compartment
with increases in CFU-O and CFU-A in the bone marrow compartment
after 3 days of dosing, increases osteoblasts on the endocortical surface
of the tibia and bone mass (μCT) at 14 days (Gambardella et al., 2011).
Therefore, GSK-3 inhibition with AZD2858 is thought to drive bone
anabolism by increasing the progenitor pool and enhancing osteoblast
differentiation in vivo.
During the formation of bone, P1NP is cleaved from the carboxy ter-
minal of the procollagenmolecule on conversion to collagen and is used
as a speciﬁc and sensitive bone turnovermarker formonitoring anabolic
treatment in humans (Chen et al., 2005). In our studies, the increase in
circulating P1NP seen after 3 and 7 days of dosing with AZD2858 is an
early indication of bone formation. This elevated level of circulating
P1NP with AZD2858 was not maintained over the 28 day period of
dosing and the reason for this is not clear. It is possible that there
may be an increased rate of clearance of P1NP from the circulation or
perhaps a lower level of bone formation occurs post-7 days which is
not detected by changes in circulating P1NP levels. Previous reports
discussing similar inconsistent rises in P1NP with longer term dosingof anabolic agents have suggested that early increases in P1NP are
followed by modest steady state levels of P1NP (Hale et al., 2007).
The other GSK-3 inhibitors (AR79 and AZ13282107) and intermit-
tent dosing with PTH1–34 produced an increase in circulating P1NP
at day 7, suggestive of a bone anabolic phenotype with these
molecules.
Theprimary biomarkers of bone resorption are degradation products
of type 1 collagen such as C-telopeptide of type 1 collagen. AZD2858
only produced a signiﬁcant increase in RatLAPS (rat CTX) at 14 days of
treatment which is similar to a previous report (Marsell et al., 2012).
In contrast, serum TRAcP-5b was reduced by day 3 and maintained
throughout the duration of the time course with AZD2858 treatment.
Therefore, this latter biomarker was used to investigate the effect of
the other two GSK-3 inhibitors as well as PTH1–34 and alendronate.
Two forms of TRAcP enzyme, TRAcP-5a and TRAcP-5b are expressed
in macrophages and osteoclasts respectively (Janckila et al., 2002). Al-
though the involvement of TRAcP in the process of bone resorption
has not been fully elucidated, TRAcP is released in signiﬁcant quantities
by bone resorbing osteoclasts and TRAcP release is clearly correlated
with the extent of bone resorption (Kirstein et al., 2006). TRAcP levels
are correlated to osteoclast numbers and TRAcP levels are elevated
in the serum of individuals who have a high rate of bone resorption
(Halleen et al., 2002). A dose related inhibition of TRAcP-5b was seen
with AZD2858, AR79 and AZ13282107 and Alendronate at 7 days
suggesting an anti-resorptive component to the activity of the GSK-3 in-
hibitors as well as the bisphosphonate. There are several different ways
that GSK-3 inhibition may affect bone resorption either directly (e.g. by
altering osteoclast numbers/function) or indirectly. Mice expressing a
stabilised form of β-catenin in osteoblasts, exhibit osteopetrosis and
reduced numbers of osteoclasts staining positive for TRAcP (Glass
et al., 2005). This may be due to upregulation of osteoprotegerin in
osteoblastic cells which in turn inhibits osteoclast differentiation and
bone resorption (Glass et al., 2005). However, there is contrasting
data where catalytically inactive GSK-3β (GSK3β-K85R) or small inter-
fering RNA (siRNA)-mediated GSK-3β silencing enhances osteoclast
formation induced by RANKL in vitro (Jang et al., 2011). GSK-3 inhibi-
tion led to increased bone mass in both mice and rats dosed daily with
AZD2858 (Gambardella et al., 2011; Marsell et al., 2012). In mice, in-
creased osteoclast number in the tibial corticoendosteal surface was
seen at day 14 with AZD2858 even though an overall increase in
bone mass was observed (Gambardella et al., 2011). However, no
change in osteoclast numbers was observed with AZD2858 treatment
in rats whereas both bone mass and strength increased (Marsell
et al., 2012). In the in vivo studies described in this manuscript, the
overall effect on bone turnover was bone anabolic conﬁrming the
bone ﬁndings with other GSK-3 inhibitors. Additional investigative
work is required to further elucidate the role of GSK-3 in osteoclast
function and bone resorption in normal bone turnover as well as in
the disease setting in vivo.
GSK-3 inhibition with AZD2858, AR79 and AZ13282107 induced
early changes in systemic P1NP and TRAcP-5b serum biomarkers of
bone turnover which were associated with histological changes in fe-
murs suggestive of bone formation at day 7. This early biomarker proﬁle
observed with GSK-3 inhibition in rats was distinct from classic anti-
resorptive bisphosphonate or anabolic PTH1–34 treatment. Longer term
dosing with AR79 over 14 days led to increased bone mass in femurs
which is similar to studies in normal mice and rats treated with
AZD2858 (Gambardella et al., 2011; Marsell et al., 2012) and consistent
with modulation of the wnt pathway using PTH, lithium chloride and
suppression of DKK1 (Clement-Lacroix et al., 2005; Monroe et al.,
2012). The bone changes seen with these GSK-3 inhibitors are most
likely to be due to inhibition of GSK-3 rather than an off-target effect
as all three compounds are potent GSK-3 inhibitors which increase
wnt signalling and stimulate mineralisation in vitro. Also, these ﬁndings
are consistent with other GSK-3 inhibitors. In addition, both AZD2858
and AZ13282107 are N70× fold selective for GSK-3 over other kinases
407P.S. Gilmour et al. / Toxicology and Applied Pharmacology 272 (2013) 399–407including HIPK2. AR79 does have equipotent activity with HIPK2 but
this enzyme currently is not known to have a role in bone remodelling.
Conclusion
These results indicate that GSK-3 inhibition causes MSC commit-
ment and differentiation to osteoblasts in human cells and produced a
net increase in bone formation consistent with the role of the canonical
Wnt signalling pathway in skeletal formation in rats. Serum biomarkers
of bone turnover, P1NP and TRAcP-5b, are early indicators of bone turn-
over modulation in rats treated with GSK-3 inhibitors which may also
be useful clinical indicators of efﬁcacy within human studies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.taap.2013.07.001.
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